DIACOMIT® (stiripentol) is an effective, FDA-approved medication that was developed specifically to treat seizures associated with Dravet syndrome. It is indicated for patients 6 months and older (weighing 15 lb or more) taking clobazam. There are no clinical data to support the use of DIACOMIT as a monotherapy.1
Explore our expanding list of resources designed to equip you with tools and research to help inform your treatment decisions.
DIACOMIT has 25 years of clinical experience and extensive data collection and analysis.7,36,37
Download this guide for information on studies illustrating DIACOMIT’s efficacy and safety profile.Download Guide
Keep this list handy to check the documented and potential drug interactions with DIACOMIT.Download Card
Review this summary of a study that investigated the perceived efficacy of DIACOMIT.Download Efficacy Poster
Review this summary of a study that explored DIACOMIT dosing practices.Download Dosing Poster
Share this brochure with caregivers of patients with Dravet syndrome to help them learn about DIACOMIT.Download Caregiver's Guide
Download forms or letters needed to complete payer requests.
Download this guide for a quick overview of our three-step access process through our specialty pharmacy.Download Access Guide
Fill out this form with your patient’s information to get them access to DIACOMIT.Download Enrollment Form
If your patient uses U.S. Department of Veterans Affairs (VA) health insurance, fill out this form to get them access to DIACOMIT.Download VA Form
Customize this letter to appeal a denied prior authorization request, formulary exception, or claim for DIACOMIT.Download Letter of Appeal
Edit this letter to provide additional information and explanation for a patient to begin treatment with DIACOMIT.Download Letter of Medical Necessity